107 related articles for article (PubMed ID: 23190892)
1. Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
Jenkins NC; Jung J; Liu T; Wilde M; Holmen SL; Grossman D
J Invest Dermatol; 2013 Apr; 133(4):1043-51. PubMed ID: 23190892
[TBL] [Abstract][Full Text] [Related]
2. A novel CDKN2A variant (p16
Li C; Liu T; Liu B; Hernandez R; Facelli JC; Grossman D
Pigment Cell Melanoma Res; 2019 Sep; 32(5):734-738. PubMed ID: 31001908
[TBL] [Abstract][Full Text] [Related]
3. Loss of Both CDKN2A and CDKN2B Allows for Centrosome Overduplication in Melanoma.
Patel S; Wilkinson CJ; Sviderskaya EV
J Invest Dermatol; 2020 Sep; 140(9):1837-1846.e1. PubMed ID: 32067956
[TBL] [Abstract][Full Text] [Related]
4. Cysteine oxidation triggers amyloid fibril formation of the tumor suppressor p16
Göbl C; Morris VK; van Dam L; Visscher M; Polderman PE; Hartlmüller C; de Ruiter H; Hora M; Liesinger L; Birner-Gruenberger R; Vos HR; Reif B; Madl T; Dansen TB
Redox Biol; 2020 Jan; 28():101316. PubMed ID: 31539802
[TBL] [Abstract][Full Text] [Related]
5. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.
Chin L; Pomerantz J; Polsky D; Jacobson M; Cohen C; Cordon-Cardo C; Horner JW; DePinho RA
Genes Dev; 1997 Nov; 11(21):2822-34. PubMed ID: 9353252
[TBL] [Abstract][Full Text] [Related]
6. NONO couples the circadian clock to the cell cycle.
Kowalska E; Ripperger JA; Hoegger DC; Bruegger P; Buch T; Birchler T; Mueller A; Albrecht U; Contaldo C; Brown SA
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1592-9. PubMed ID: 23267082
[TBL] [Abstract][Full Text] [Related]
7. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.
Li J; Poi MJ; Tsai MD
Biochemistry; 2011 Jun; 50(25):5566-82. PubMed ID: 21619050
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas.
MacKie RM; Andrew N; Lanyon WG; Connor JM
J Invest Dermatol; 1998 Aug; 111(2):269-72. PubMed ID: 9699728
[TBL] [Abstract][Full Text] [Related]
9. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
Nykamp K; Anderson M; Powers M; Garcia J; Herrera B; Ho YY; Kobayashi Y; Patil N; Thusberg J; Westbrook M; ; Topper S
Genet Med; 2017 Oct; 19(10):1105-1117. PubMed ID: 28492532
[TBL] [Abstract][Full Text] [Related]
10. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.
Bodian DL; McCutcheon JN; Kothiyal P; Huddleston KC; Iyer RK; Vockley JG; Niederhuber JE
PLoS One; 2014; 9(4):e94554. PubMed ID: 24728327
[TBL] [Abstract][Full Text] [Related]
11. The p16INK4a/CDKN2A tumor suppressor and its relatives.
Ruas M; Peters G
Biochim Biophys Acta; 1998 Oct; 1378(2):F115-77. PubMed ID: 9823374
[No Abstract] [Full Text] [Related]
12. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.
Momozawa Y; Iwasaki Y; Parsons MT; Kamatani Y; Takahashi A; Tamura C; Katagiri T; Yoshida T; Nakamura S; Sugano K; Miki Y; Hirata M; Matsuda K; Spurdle AB; Kubo M
Nat Commun; 2018 Oct; 9(1):4083. PubMed ID: 30287823
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
Hart SN; Hoskin T; Shimelis H; Moore RM; Feng B; Thomas A; Lindor NM; Polley EC; Goldgar DE; Iversen E; Monteiro ANA; Suman VJ; Couch FJ
Genet Med; 2019 Jan; 21(1):71-80. PubMed ID: 29884841
[TBL] [Abstract][Full Text] [Related]
14. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Richards S; Aziz N; Bale S; Bick D; Das S; Gastier-Foster J; Grody WW; Hegde M; Lyon E; Spector E; Voelkerding K; Rehm HL;
Genet Med; 2015 May; 17(5):405-24. PubMed ID: 25741868
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
16. Focus on the Contribution of Oxidative Stress in Skin Aging.
Papaccio F; D Arino A; Caputo S; Bellei B
Antioxidants (Basel); 2022 Jun; 11(6):. PubMed ID: 35740018
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Bioactive Properties of Lipophilic Fractions of Edible and Non-Edible Parts of
Kyriakou S; Tragkola V; Alghol H; Anestopoulos I; Amery T; Stewart K; Winyard PG; Trafalis DT; Franco R; Pappa A; Panayiotidis MI
Pharmaceuticals (Basel); 2022 Jan; 15(2):. PubMed ID: 35215254
[TBL] [Abstract][Full Text] [Related]
18. TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis.
Wang Y; Chen Y; Li C; Xiao Z; Yuan H; Zhang Y; Pang D; Tang X; Li M; Ouyang H
Biology (Basel); 2022 Jan; 11(1):. PubMed ID: 35053139
[TBL] [Abstract][Full Text] [Related]
19. Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.
Kimura H; Paranal RM; Nanda N; Wood LD; Eshleman JR; Hruban RH; Goggins MG; Klein AP; ; Roberts NJ
Elife; 2022 Jan; 11():. PubMed ID: 35001868
[TBL] [Abstract][Full Text] [Related]
20. Study on Early Onset Melanoma and Germ-Line Mutation in CDKN2A among Patients in Imam Khomeini Hospital Complex.
Ferdosi S; Saffari M; Alishahi R; Ghanadan A; Shirkohi R
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3347-3353. PubMed ID: 34711012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
